Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
Status:
Withdrawn
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral
density in osteoporotic postmenopausal women who were previously treated with alendronate.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Alendronate Calcium Calcium Carbonate Cholecalciferol Vitamin D